Thrombophilia, Thrombosis and Pregnancy

Amiram Eldor

doi:10.1055/s-0037-1616206

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 86(01): 104-111
DOI: 10.1055/s-0037-1616206

Research Article

Schattauer GmbH

Thrombophilia, Thrombosis and Pregnancy

Amiram Eldor

Institute of Hematology, Tel-Aviv Sourasky Medical Center, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

› Institutsangaben

Abstract

Summary

The risk of venous thromboembolism (VTE) in pregnancy is 0.05-1.8%, six times greater than in the non-pregnant state, and pulmonary embolism remains the most common cause of maternal death. Maternal age, previous history of VTE, Caesarean section and the presence of thrombophilia, significantly increase the risk of VTE. Acquired or hereditary thrombophilia occur in almost two-thirds of women presenting with recurrent miscarriages, pre-eclampsia, intrauterine growth restriction, abruptio placentae, or stillbirth, which are associated with microvascular thrombosis in placental blood vessels. Women with VTE during pregnancy and especially those with thrombophilia require individualized management, based on the type of defect, the family history and the presence of additional risk factors. These factors are important in determining the dose and duration of antithrombotic therapy during pregnancy and the puerperium, and the thromboprophylactic strategy for future pregnancies. Oral anticoagulants are now seldom used during pregnancy because of their significant side effects. Low-molecular-weight heparins (LMWHs) are increasingly replacing unfractionated heparin in the prevention and treatment of VTE during pregnancy. LMWHs have also been shown to be effective in improving the outcome of pregnancy in women with previous obstetric complications.

Key words

Pregnancy - venous thromboembolism - thrombophilia - obstetric complications - low-molecular-weight heparin

Volltext

Referenzen

References
1 Dahlbäck B. Molecular genetics of venous thromboembolism. Ann Med 1995; 27: 187-92.
2 Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-20.
3 De SV, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 71: 799-800.
4 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. Common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
5 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
6 den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
7 Lockshin MD. Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost 1999; 82: 641-8.
8 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301.
9 Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-80.
10 Greer IA. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med 2000; 342: 424-5.
11 Greer IA. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology. Clin Obstet Gynaecol 1997; 11: 403-30.
12 Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-65.
13 Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 1997; 104: 191-7.
14 Turnball A, Tindall VR, Beard RW. Report on confidential enquiries into maternal death in England and Wales 1982-1984. London: HMSO; 1989. Report No. 28.
15 Barracco MA, Vessey M. Recurrence of venous thromboembolism and the use of oral contraceptives. Br Med J 1974; 2: 215.
16 Ginsberg JS, Brill-Edwards P, Burrows RF, Bona R, Prandoni P, Buller HR, Lensing A. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67: 519-20.
17 Friend JR, Kakkar VV. The diagnosis of deep venous thrombosis in the puerperium. J Obstet Gynaecol Br Commonw 1970; 77: 820.
18 Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J 1996; 41: 83-6.
19 Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost 1994; 71: 15-8.
20 Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, Prandoni P, Buller HR, Girolami A, Prins MH. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125: 955-60.
21 Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-70.
22 Hallak M, Senderowicz J, Cassel A, Shapira C, Aghai E, Auslender R, Abramovici H. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176: 889-93.
23 Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-8.
24 Shu H, Wramsby M, Bokarewa M, Blombäck M, Bremme K. Decrease in protein C inhibitor activity and acquired APC resistance during normal pregnancy. J Thromb Thrombolysis 2000; 9: 277-81.
25 Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-7.
26 Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
27 McColl MD, Ellison J, Reid F, Tait R.C., Walker ID, Greer IA. Prothrombin 20210 G A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol 2000; 107: 565-9.
28 Lindqvist PG, Svensson PJ, Dahlback B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss – a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73.
29 Dunnihoo DR, Gallaspy JW, Wise RB, Otterson WN. Postpartum ovarian vein thrombophlebitis: a review. Obstet Gynecol Surv 1991; 46: 415-27.
30 Salomon O, Apter S, Shaham D, Hiller N, Bar-Ziv J, Itzchak Y, Gitel S, Rosenberg N, Strauss S, Kaufman N, Seligsohn U. Risk factors associated with postpartum ovarian vein thrombosis. Thromb Haemost 1999; 82: 1015-9.
31 Twickler DM, Setiawan AT, Evans RS, Erdman WA, Stettler RW, Brown CE, Cunningham FG. Imaging of puerperal septic thrombophlebitis: prospective comparison of MR imaging, CT, and sonography. Am J Roentgenol 1997; 169: 1039-43.
32 Lanska DJ, Kryscio RJ. Stroke and intracranial venous thrombosis during pregnancy and puerperium. Neurology 1998; 51: 1622-8.
33 Mas JL, Lamy C. Stroke in pregnancy and the puerperium. J Neurol 1998; 245: 305-13.
34 Kittner SJ, Stern BJ, Feeser BR, Hebel R, Nagey DA, Buchholz DW, Earley CJ, Johnson CJ, Macko RF, Sloan MA, Wityk RJ, Wozniak MA. Pregnancy and the risk of stroke. N Engl J Med 1996; 335: 768-74.
35 Ruiz-Irastorza G, Khamashta MA, Hughes GRV. Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: Maternal and fetal complications and their management. Israel Med Assoc J 2000; 2: 462-9.
36 Rizk B, Meagher S, Fisher AM. Severe ovarian hyperstimulation syndrome and cerebrovascular accidents. Hum Reprod 1990; 5: 697-8.
37 Lamy C, Hamon JB, Coste J, Mas JL. Ischemic stroke in young women: risk of recurrence during subsequent pregnancies. French Study Group on Stroke in Pregnancy. Neurology 2000; 55: 269-74.
38 Kupferminc MJ, Yair D, Bornstein NM, Lessing JB, Eldor A. Transient focal neurological deficits during pregnancy in carriers of inherited thrombophilia. Stroke 2000; 31: 892-5.
39 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
40 Infante-Rievard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med 1991; 325: 1063-6.
41 Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 131-6.
42 Rai RS, Regan L, Chitolie A, Donald JG, Cohen H. Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br J Obstet Gynaecol 1996; 103: 842-4.
43 Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini D, Martinelli P, Montanaro S, Pavone G, Di Minno G. Factor V Leiden, C T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997; 77: 1052-4.
44 Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997; 177: 402-5.
45 Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini D, Martinelli P, Montanaro S, Pavone G, Di Minno G. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77: 822-4.
46 Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, Blumenfeld Z. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97: 551-4.
47 Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
48 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
49 Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der Meer FJ. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
50 Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, ten Cate JW. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75: 387-8.
51 Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 1000-3.
52 Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlbäck B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532-7.
53 Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, Bozzo M, Mannucci PM. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-8.
54 Deitcher SR, Park VM, Kutteh WH. Prothrombin 20210 GA mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood 1998; 92 (Suppl. 01) 118b.
55 Durnwald CP, Flora R, Agamanolis D, Spirtos N, Steele M, Galehouse D. Hereditary thrombophilia as a cause of fetal loss. Obstet Gynecol 2000; 95: S11-2.
56 Yamada H, Kato EH, Ebina Y, Kishida T, Hoshi N, Kobashi G, Sakuragi N, Fujimoto S. Factor XII deficiency in women with recurrent miscarriage. Gynecol Obstet Invest 2000; 49: 80-3.
57 Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks’ gestation: associated placental pathologic features. Am J Obstet Gynecol 1995; 173: 1049-57.
58 Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, Eldor A. Increased frequency of the hypofibrinolytic 4G/4G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene in women with obstetric complications. Obstet Gynecol. 2001 in press.
59 Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999; 48: 1589-95.
60 Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000; 96: 45-9.
61 van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. Br J Obstet Gynaecol 2000; 107: 785-91.
62 Vern TZ, Alles AJ, Kowal-Vern A, Longtine J, Roberts DJ. Frequency of factor V (Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions. Hum Pathol 2000; 31: 1036-43.
63 de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997; 104: 1248-54.
64 Goddijn-Wessel TA, Wouters MG, van de Molen EF, Spuijbroek MD, Steegers-Theunissen RP, Blom HJ, Boers GH, Eskes TK. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996; 66: 23-9.
65 Vollsett SE, Bjorke-Monsen AAL, Igrens LM. Plasma total homocysteine and previous pregnancies: the Hordaland homocysteine study. Proceedings of the 2nd International Symposium on Homocysteine. Neth J Med 1998; 52: S54.
66 Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998; 114 (Suppl. 05) 524S-30S.
67 Ginsberg JS, Hirsh J, Rainbow AJ, Coates G. Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 1989; 61: 189-96.
68 Gillis S, Shushan A, Eldor A. Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynaecol Obstet 1992; 39: 297-301.
69 Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, Nicolaides KH, Barrett JJ, Kakkar VV. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-6.
70 Fejgin MD, Lourwood DL. Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv 1994; 49: 424-31.
71 Hunt BJ, Doughty HA, Majumdar G, Copplestone A, Kerslake S, Buchanan N, Hughes G, Khamashta M. Thromboprophylaxis with low molecular weight heparin (fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.
72 Nelson-Piercy C, Letsky EA, De Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176: 1062-8.
73 Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, LavennePardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, Mac Gillavry MR, Hamulyak K, Theunissen IM, Hunt BJ, Buller HR. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72.
74 Harenberg J, Schneider D, Heilmann L, Wolf H. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 1993; 23: 314-20.
75 Bertina RM, Rosendaal FR. Venous thrombosis – the interaction of genes and environment. N Engl J Med 1998; 338: 1840-1.
76 Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson KS, Whittom R, Couture G. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343: 1439-44.
77 Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995; 173: 1240-5.
78 Barbour LA, Smith JM, Marlar RA. Heparin levels to guide thromboembolism prophylaxis during pregnancy. Am J Obstet Gynecol 1995; 173: 1869-73.
79 Eldor A. Applying risk assessment models in non-surgical patients: effective risk stratification. Blood Coagul Fibrinolysis 1999; 10 (Suppl. 02) S91-7.
80 Conard J, Horellou M, Samama MM. Management of pregnancy in women with thrombophilia. Haemostasis 1999; 29 Suppl S1 98-104.
81 Hirsh J. Low-molecular-weight heparin for the treatment of venous thromboembolism. Am Heart J 1998; 135 6 Pt 3 Suppl S336-42.
82 Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med 2000; 9: 122-5.
83 Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999; 96: 275-82.
84 Ensom MH, Stephenson MD. Low-molecular-weight heparins in pregnancy. Pharmacotherapy 1999; 19: 1013-25.
85 Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynaecol 2000; 107: 1116-21.
86 Aburahma AF, Boland JP. Management of deep vein thrombosis of the lower extremity in pregnancy: a challenging dilemma. Am Surg 1999; 65: 164-7.
87 Cowchock S. Treatment of antiphospholipid syndrome in pregnancy. Lupus 1998; 7 (Suppl. 02) S95-7.
88 Hunt BJ, Khamashta MA, Lakasing L, Williams FMK, Nelson-Piercy C, Bewley S, Hughes GRV. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable?. Thromb Haemost 1998; 79: 1060-1.
89 Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 338: 701-5.
90 Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996; 35: 402-7.
91 Gris JC, Neveu S, Tailand ML, Courtieu C, Mares P, Schved JF. Use of low-molecular-weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thromb Haemost 1995; 73: 362-7.
92 Brenner B. Inherited thrombophilia and pregnancy loss. Thromb Haemost 1999; 82: 634-40.
93 Younis JS, Ohel G, Brenner B, Haddad S, Lanir N, Ben-Ami M. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. Br J Obstet Gynaecol 2000; 107: 415-9.
94 Bar J, Cohen-Sacher B, Hod M, Blickstein D, Lahav J, Merlob P. Low-molecular-weight heparin for thrombophilia in pregnant women. Int J Gynaecol Obstet 2000; 69: 209-13.
95 Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, Eldor A. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertension in Pregnancy. 2001 in press.
96 Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998; 80: 49-54.
97 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-9.
98 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-7.
99 Branch DW, Peaceman AM, Druzin M, Silver RK, El Sayed Y, Silver RM, Esplin MS, Spinnato J, Harger J. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000; 182: 122-7.